Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more
Chengdu Olymvax Biopharmaceuticals Inc. A (688319) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, Chengdu Olymvax Biopharmaceuticals Inc. A (688319) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥52.89 Million) by net assets (CN¥968.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chengdu Olymvax Biopharmaceuticals Inc. A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Chengdu Olymvax Biopharmaceuticals Inc. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chengdu Olymvax Biopharmaceuticals Inc. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Olymvax Biopharmaceuticals Inc. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Zijiang Enterprise Group Co Ltd
SHG:600210
|
0.077x |
|
alstria office REIT-AG
XETRA:AOX
|
-0.004x |
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
-0.102x |
|
Guangdong Topstar Technology Co Ltd
SHE:300607
|
0.012x |
|
ODFJELL DRILL.LTD. DL-01
F:OD3
|
N/A |
|
Tata Technologies Limited
NSE:TATATECH
|
0.037x |
|
Premier Energies Limited
NSE:PREMIERENE
|
0.064x |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
0.025x |
Annual Cash Flow Conversion Efficiency for Chengdu Olymvax Biopharmaceuticals Inc. A (2013–2024)
The table below shows the annual cash flow conversion efficiency of Chengdu Olymvax Biopharmaceuticals Inc. A from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥933.50 Million | CN¥-9.73 Million | -0.010x | -122.05% |
| 2023-12-31 | CN¥930.77 Million | CN¥44.00 Million | 0.047x | +271.74% |
| 2022-12-31 | CN¥891.85 Million | CN¥-24.55 Million | -0.028x | -158.18% |
| 2021-12-31 | CN¥844.66 Million | CN¥39.96 Million | 0.047x | -15.43% |
| 2020-12-31 | CN¥376.97 Million | CN¥21.09 Million | 0.056x | +145.65% |
| 2019-12-31 | CN¥340.84 Million | CN¥-41.77 Million | -0.123x | -42.75% |
| 2018-12-31 | CN¥194.48 Million | CN¥-16.70 Million | -0.086x | +14.75% |
| 2017-12-31 | CN¥213.49 Million | CN¥-21.50 Million | -0.101x | +56.14% |
| 2016-12-31 | CN¥185.37 Million | CN¥-42.56 Million | -0.230x | -78.92% |
| 2015-12-31 | CN¥210.69 Million | CN¥-27.04 Million | -0.128x | -35.94% |
| 2014-12-31 | CN¥143.12 Million | CN¥-13.51 Million | -0.094x | +17.77% |
| 2013-12-31 | CN¥168.06 Million | CN¥-19.29 Million | -0.115x | -- |